Literature DB >> 20660685

In vivo efficacy of anidulafungin against mature Candida albicans biofilms in a novel rat model of catheter-associated Candidiasis.

Sona Kucharíková1, Hélène Tournu, Michelle Holtappels, Patrick Van Dijck, Katrien Lagrou.   

Abstract

The present study demonstrates the efficacy of anidulafungin on mature Candida albicans biofilms in vivo. One hundred fifty-seven catheter fragments challenged with C. albicans were implanted subcutaneously in rats. After formation of biofilms, rats were treated with daily intraperitoneal injections of anidulafungin for 7 days. Catheters retrieved from treated animals showed reduced cell numbers compared to those retrieved from untreated and fluconazole-treated animals. Systemic administration of anidulafungin is promising for the treatment of mature C. albicans biofilms.

Entities:  

Mesh：

Substances：

Year:  2010        PMID： 20660685      PMCID： PMC2944565          DOI： 10.1128/AAC.00697-10

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  11 in total

Review 1.  Guidelines for the management of intravascular catheter-related infections.

Authors:  L A Mermel; B M Farr; R J Sherertz; I I Raad; N O'Grady; J S Harris; D E Craven
Journal:  Clin Infect Dis       Date:  2001-04-03       Impact factor: 9.079

2.  Evaluation of caspofungin and amphotericin B deoxycholate against Candida albicans biofilms in an experimental intravascular catheter infection model.

Authors:  Jennifer A Shuford; Mark S Rouse; Kerryl E Piper; James M Steckelberg; Robin Patel
Journal:  J Infect Dis       Date:  2006-07-28       Impact factor: 5.226

3.  Standardized method for in vitro antifungal susceptibility testing of Candida albicans biofilms.

Authors:  G Ramage; K Vande Walle; B L Wickes; J L López-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2001-09       Impact factor: 5.191

4.  Candida albicans biofilm formation in a new in vivo rat model.

Authors:  Markéta Řičicová; Soňa Kucharíková; Hélène Tournu; Jelle Hendrix; Helena Bujdáková; Johan Van Eldere; Katrien Lagrou; Patrick Van Dijck
Journal:  Microbiology       Date:  2009-12-03       Impact factor: 2.777

5.  Development and characterization of an in vivo central venous catheter Candida albicans biofilm model.

Authors:  D Andes; J Nett; P Oschel; R Albrecht; K Marchillo; A Pitula
Journal:  Infect Immun       Date:  2004-10       Impact factor: 3.441

6.  Dispersion as an important step in the Candida albicans biofilm developmental cycle.

Authors:  Priya Uppuluri; Ashok K Chaturvedi; Anand Srinivasan; Mohua Banerjee; Anand K Ramasubramaniam; Julia R Köhler; David Kadosh; Jose L Lopez-Ribot
Journal:  PLoS Pathog       Date:  2010-03-26       Impact factor: 6.823

7.  Rabbit model of Candida albicans biofilm infection: liposomal amphotericin B antifungal lock therapy.

Authors:  Matthew K Schinabeck; Lisa A Long; Mohammad A Hossain; Jyotsna Chandra; Pranab K Mukherjee; Sotohy Mohamed; Mahmoud A Ghannoum
Journal:  Antimicrob Agents Chemother       Date:  2004-05       Impact factor: 5.191

8.  Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis.

Authors:  Anna L Lazzell; Ashok K Chaturvedi; Christopher G Pierce; Deepthi Prasad; Priya Uppuluri; Jose L Lopez-Ribot
Journal:  J Antimicrob Chemother       Date:  2009-07-07       Impact factor: 5.790

9.  Isolation of the Candida albicans gene for orotidine-5'-phosphate decarboxylase by complementation of S. cerevisiae ura3 and E. coli pyrF mutations.

Authors:  A M Gillum; E Y Tsay; D R Kirsch
Journal:  Mol Gen Genet       Date:  1984

10.  Paradoxical growth effects of the echinocandins caspofungin and micafungin, but not of anidulafungin, on clinical isolates of Candida albicans and C. dubliniensis.

Authors:  M Fleischhacker; C Radecke; B Schulz; M Ruhnke
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12-04       Impact factor: 3.267
View more
  23 in total

1.  Micafungin at physiological serum concentrations shows antifungal activity against Candida albicans and Candida parapsilosis biofilms.

Authors:  M Guembe; J Guinea; L J Marcos-Zambrano; A Fernández-Cruz; T Peláez; P Muñoz; E Bouza
Journal:  Antimicrob Agents Chemother       Date:  2014-06-23       Impact factor: 5.191

2.  Favorable outcome of neonatal cerebrospinal fluid shunt-associated Candida meningitis with caspofungin.

Authors:  Jop Jans; Roger J M Brüggemann; V Christmann; Paul E Verweij; Adilia Warris
Journal:  Antimicrob Agents Chemother       Date:  2013-02-25       Impact factor: 5.191

3.  From Biology to Drug Development: New Approaches to Combat the Threat of Fungal Biofilms.

Authors:  Christopher G Pierce; Anand Srinivasan; Anand K Ramasubramanian; José L López-Ribot
Journal:  Microbiol Spectr       Date:  2015-06

Review 4.  Pathogenesis of Candida albicans biofilm.

Authors:  Christina Tsui; Eric F Kong; Mary Ann Jabra-Rizk
Journal:  Pathog Dis       Date:  2016-06       Impact factor: 3.166

5.  Candida albicans biofilm development on medically-relevant foreign bodies in a mouse subcutaneous model followed by bioluminescence imaging.

Authors:  Soňa Kucharíková; Greetje Vande Velde; Uwe Himmelreich; Patrick Van Dijck
Journal:  J Vis Exp       Date:  2015-01-27       Impact factor: 1.355

6.  Activities of systemically administered echinocandins against in vivo mature Candida albicans biofilms developed in a rat subcutaneous model.

Authors:  Sona Kucharíková; Nidhi Sharma; Isabel Spriet; Johan Maertens; Patrick Van Dijck; Katrien Lagrou
Journal:  Antimicrob Agents Chemother       Date:  2013-02-12       Impact factor: 5.191

7.  Antifungal Activity of Oleylphosphocholine on In Vitro and In Vivo Candida albicans Biofilms.

Authors:  Michelle Holtappels; Erwin Swinnen; Lies De Groef; Jurgen Wuyts; Lieve Moons; Katrien Lagrou; Patrick Van Dijck; Soňa Kucharíková
Journal:  Antimicrob Agents Chemother       Date:  2017-12-21       Impact factor: 5.191

8.  Oral administration of the broad-spectrum antibiofilm compound toremifene inhibits Candida albicans and Staphylococcus aureus biofilm formation in vivo.

Authors:  Kaat De Cremer; Nicolas Delattin; Katrijn De Brucker; Annelies Peeters; Soña Kucharíková; Evelien Gerits; Natalie Verstraeten; Jan Michiels; Patrick Van Dijck; Bruno P A Cammue; Karin Thevissen
Journal:  Antimicrob Agents Chemother       Date:  2014-10-06       Impact factor: 5.191

9.  Candida biofilms and the host: models and new concepts for eradication.

Authors:  Hélène Tournu; Patrick Van Dijck
Journal:  Int J Microbiol       Date:  2011-11-14

10.  Risk factors and outcomes of candidemia caused by biofilm-forming isolates in a tertiary care hospital.

Authors:  Mario Tumbarello; Barbara Fiori; Enrico Maria Trecarichi; Patrizia Posteraro; Angela Raffaella Losito; Alessio De Luca; Maurizio Sanguinetti; Giovanni Fadda; Roberto Cauda; Brunella Posteraro
Journal:  PLoS One       Date:  2012-03-30       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.